Chief Scientific Officer
Vega Therapeutics
South San Francisco, California, United States
My name is Sandip Panicker, PhD, and I am the co-founder and Chief Scientific Officer of Vega Therapeutics. My career in drug development began in 2007 at Roche Pharmaceuticals, California, studying immunology. After Roche, I joined iPierian, a small biotech in the San Francisco Bay Area where I headed the biology discovery efforts for a first-in-class monoclonal antibody targeting C1s, a protein in the complement cascade. This program was spun out into a company called True North Therapeutics that developed sutimlimab (ENJAYMO), the first approved therapeutic for cold agglutinin disease by the FDA, EMA and Japanese regulatory authorities. I have since joined Star Therapeutics and have been overseeing the research efforts for its subsidiary companies Electra Therapeutics, Vega Therapeutics, and Polaris Therapeutics. At Vega Therapeutics, we are developing a first-in-class Protein S monoclonal antibody for the treatment of congenital bleeding disorders, currently focusing on von Willebrand Disease.
Tuesday, June 27, 2023
18:30 - 19:30 ET